PMID: 2494640Jan 1, 1989Paper

Long-term tobramycin aerosol therapy in cystic fibrosis

Pediatric Pulmonology
G SteinkampH von der Hardt

Abstract

The long-term efficacy and safety of aminoglycoside aerosol therapy for Pseudomonas aeruginosa colonization/infection in cystic fibrosis has not been fully investigated. In the present study, 14 patients with cystic fibrosis, ages 8-19 years (mean: 13.3 years), received tobramycin aerosol therapy for a mean duration of 20 months. Eighty milligrams of a tobramycin solution were inhaled twice daily after physiotherapy via a jet nebulizer. After 1 year, weight for height increased significantly by 2.9% of the predicted normal, and the Kraemer clinical score increased by 2.1 points (P less than 0.05). The frequency of hospital admissions decreased from 2.0 to 1.3 per patient, respectively, during the years before and after the study onset. The antibody response to P. aeruginosa elastase, exotoxin A, and alkaline phosphatase showed a reduction in serum titers against one or more enzymes in eight patients. The best long-term results after 12-38 months of treatment were obtained in moderately ill children. No evidence of ototoxicity or renal damage was observed. Although intermittent bacterial resistance occurred in five patients after 10-21 months of tobramycin inhalation, this was not associated with clinical deterioration. The stud...Continue Reading

References

Oct 1, 1979·Archives of Dermatology·J J LeydenO H Mills
Dec 9, 1976·European Journal of Pediatrics·H von der Hardt, M Leben
Dec 1, 1986·European Journal of Pediatrics·G SteinkampJ H Ehrich
Jan 1, 1986·Annual Review of Microbiology·N HøibyP O Schiøtz
Nov 1, 1987·Acta paediatrica Scandinavica·S S PedersenE W Flensborg
May 1, 1986·The Journal of Pediatrics·I MacLuskyF J McLaughlin
Feb 1, 1974·Journal of Clinical Pathology· Shriniwas
Jan 1, 1973·Archives of Internal Medicine·B O Stuart
Apr 1, 1974·The Journal of Pediatrics·P O AldersonR L Hill
Apr 1, 1983·The Journal of Infectious Diseases·G DöringA Hofmann
Jul 1, 1984·Journal of Clinical Microbiology·J A FyfeJ R Govan
Mar 1, 1984·Australian Paediatric Journal·P KunP D Phelan
May 15, 1980·The New England Journal of Medicine·C R SmithP S Lietman
Jan 1, 1974·Pediatric Radiology·A R Chrispin, A P Norman

❮ Previous
Next ❯

Citations

Jan 1, 1995·Pediatric Pulmonology. Supplement·A L Smith, B Ramsey
Feb 28, 2003·Lancet·Felix Ratjen, Gerd Döring
Nov 30, 2002·Advanced Drug Delivery Reviews·Lucila Garcia-Contreras, Anthony J Hickey
Feb 13, 2001·International Journal of Antimicrobial Agents·F Ratjen
Jun 17, 1993·The New England Journal of Medicine·B W RamseyM A McBurnie
Jul 18, 1996·The New England Journal of Medicine·B W Ramsey
Dec 4, 1994·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·M A el-DinM S Gabr
Aug 18, 2000·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·T TodiscoM Knoch
Sep 2, 2008·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Elsbeth M WestermanHarry G M Heijerman
Sep 20, 2012·Current Opinion in Pulmonary Medicine·A George F DavidsonYolanda P Lillquist
Feb 1, 1992·Journal of Paediatrics and Child Health·K Grimwood
Jan 15, 2011·Clinical Microbiology Reviews·Alan R HauserSusanna A McColley
Jun 1, 1993·Archives of Disease in Childhood·J M LittlewoodH Cunliffe
Dec 1, 1995·Archives of Disease in Childhood·C S Beardsmore
Mar 23, 1999·Archives of Disease in Childhood·S P Conway
Mar 23, 1999·Archives of Disease in Childhood·M Sood, I W Booth
Aug 10, 2000·American Journal of Respiratory and Critical Care Medicine·A F BarkerJ Quan
Oct 14, 2003·American Journal of Respiratory and Critical Care Medicine·Ronald L GibsonBonnie W Ramsey
Sep 1, 2007·American Journal of Respiratory and Critical Care Medicine·Patrick A FlumeUNKNOWN Cystic Fibrosis Foundation, Pulmonary Therapies Committee
Jan 1, 1993·The Journal of Clinical Investigation·A Cantin, D E Woods
May 16, 2002·Pharmacotherapy·Michael J AsmusRichard C Ahrens
Jun 27, 2002·Paediatric Drugs·Isabelle Sermet-GaudelusGérard Lenoir
May 1, 1992·European Journal of Pediatrics·G KusenbachH Döhmen
Mar 2, 2010·Infection·A Michalopoulos, E Papadakis
Jun 3, 2014·Expert Review of Respiratory Medicine·Valerie Waters, Felix Ratjen
Feb 21, 2007·Expert Opinion on Pharmacotherapy·Jennifer K HagermanMichael E Klepser
Jun 23, 2009·Expert Opinion on Drug Safety·Amar SafdarBurton F Dickey
Jul 30, 2009·Expert Opinion on Drug Delivery·Daniela Traini, Paul M Young
Sep 24, 1999·Chest·P W Campbell, L Saiman
Feb 1, 1992·Chest·G F AlvineR C Ahrens
Jan 22, 2004·Chest·James R YankaskasDavid Rodman
May 1, 1999·Antimicrobial Agents and Chemotherapy·M P Mingeot-Leclercq, P M Tulkens
Aug 10, 2010·Paediatric Respiratory Reviews·Bridget StuartPeter J Mogayzel
May 13, 1999·Mayo Clinic Proceedings·R S Edson, C L Terrell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.